PBCT People's United Financial Inc

LPI Laredo Petroleum Inc

LOW Lowe's Companies Inc

LNG Cheniere Energy Inc

LNC Lincoln National Corp

LITE Lumentum Holdings Inc

LH Laboratory Corporation of America Holdings

ZTE Corporation is a China-based company principally engaged in the design, development, production, distribution and installation of a range of Information and Communication Technology (ICT) related systems, equipment and terminals. The Company mainly operates its business through three segments: Carriers’ Network segment, Government and Corporate segment and Consumer segment. Carriers’ Network segment mainly provides wireless network, wired network, core network and telecommunication software systems and services, as well as other technologies and product solutions. Government and Corporate segment provides the government and corporate information projects with top-level design, consulting services and integrated information solutions. Consumer segment is mainly involved in the development, production and sale of smart phones, mobile data terminals, family terminals and wearable devices, as well as the provision of related software applications and value-added services.

There were three reasons that Canopy executives and analysts pointed to for the revenue growth: Recreational weed sales grew, especially compared with the results Aurora reported Thursday; the domestic and international medical marijuana business ticked up, potentially due to Aurora's struggles; and the company's marijuana-paraphernalia acquisitions grew sales nearly 50%, while most Canadian cannabis companies, including Aurora, have not acquired large, established accessories businesses.

"Our top-line performance benefited from a broad base of growth in our core cannabis business, as well as our strategic acquisitions," Canopy Chief Financial Officer Mike Lee said in a conference call Friday.

"Canopy does not need to chase sub-value pricing. Canopy's recreational portfolio is balanced between tiers (40% premium, 30% mainstream, 30% value) with broad momentum, and it will not chase sub-value pricing," Piper Sandler analyst Michael Lavery wrote in a note to clients Friday. Lavery raised his target price to $28 after the results and has the equivalent of a buy rating on Canopy stock.

The company's business-to-consumer sales also increased, which was in part a result of owning its own retail operations. Canopy added 12 retail locations during the quarter to bring its total retail footprint to 27 across the country, and increased same-store sales 11%. Aurora opted to become involved in retail operations via its investment in Alberta-based liquor retailer Alcanna Inc. (CLIQ.T) instead of running its own retail shops.

Canopy's medical cannabis sales expanded in the fiscal third quarter both in Canada and overseas, with the latter possibly helped by Aurora's struggles. Aurora's international sales declined in part because Germany held up some product Aurora shipped to patients in that country.

"Our sales in Germany benefited from opportunistic sales to fill supply gaps created by a regulatory hold on products of another vendor," Lee said in the earnings call.

A number of Canopy Growth's acquisitions showed growth as well, amounting to a total of 22% of its revenue, with hardware used to consume marijuana a key focus. Its cannabinoid medicine maker C3 grew revenue by 5% versus the prior quarter. Vaporizer sales from its Storz & Bickle acquisition grew 46% over the last quarter, because of "organic growth" and the company' benefited from seasonal sales of roughly C$5 million.

Storz & Bickle makes a number of cannabis consumption accessories, including vape devices, which includes the venerable Volcano, well-known among cannabis enthusiasts even prior to Canopy buying the German company. Other hardware acquisitions This Works and Biosteel also boosted the company's sales, Lee said.

It was not all good news for Canopy, however. Jefferies analyst Owen Bennett wrote in a note to clients early Friday that while the headline numbers will "provide relief," areas of concern remain in the details.

Bennett said the company's market share declined to 22%, despite the fact that the company nearly doubled its retail footprint; Canopy also issued guidance with a "modest" fiscal fourth-quarter sales increase, which suggests their market share will continue to decline. Bennett has the equivalent of a sell rating on the name with a C$21 target price.

U.S.-traded shares of Canopy Growth have lost half their value in the past year as the S&P 500 has gained 23%. The ETFMG Alternative Harvest ETF (MJ) has fallen 53% in the past year and the Horizons Marijuana Life Sciences Index ETF fell 60%.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may
expose investors to potentially rapid and substantial losses.Please read Characteristics and Risks of Standard Options before investing in options.